Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Asklep to Set Up 3rd East Asian Subsidiary in South Korea
October 17, 2012
- Denosumab Significantly Reduces Vertebral Fractures in Osteoporosis Patients in PIII Study: Daiichi Sankyo
October 17, 2012
- Asahi Glass Offers CMO Services to Biopharmaceutical Industry Using ASPEX Technology: Dr Kumagai
October 17, 2012
- MediciNova to Bring Japanese Pharma Synthesized Drug Candidates to the World: Dr Matsuda
October 17, 2012
- Qol to Fully Enter CSO Market thru Apo Plus Acquisition, Mr Takada to Be Director
October 16, 2012
- MTPC’s Oral MS Treatment Charging towards Blockbuster Territory
October 16, 2012
- Hospira Files Public Knowledge-Based Application for Generic Gemcitabine for Malignant Lymphoma
October 16, 2012
- Towa Pharmaceutical Expanding Direct-Sales Network as Its Distributors Face Lack of Successors
October 15, 2012
- Pirespa Debuts in South Korea through Ildong: Shionogi
October 15, 2012
- Long-Term Investments in Developing Countries Expects Returns from 2020: President Naito of Eisai
October 15, 2012
- Radical AD Treatments Hit “PIII Wall” Again, but Amyloid β Hypothesis Remains Unshaken
October 15, 2012
- Meiji Seika Pharma to Solely Market 3 Diagnostics for Infectious Diseases
October 12, 2012
- Hisamitsu Posts 4.0% Sales Increase in March-August by Market Share Recovery of Mohrus Tape Series
October 12, 2012
- Eisai to Dissolve, Absorb Its Diagnostics Research Subsidiary Palma Bee’Z
October 12, 2012
- AVEO Files NDA for Tivozanib in US: Astellas
October 12, 2012
- Ajinomoto, Astellas to Codevelop Nateglinide for Combination Use with DPP-4 Inhibitors
October 11, 2012
- MTPC, Kureha Fail to Meet Primary Goal in Global PIII Studies for Kremezin
October 11, 2012
- Kyorin to Transfer Pekiron to Galderma
October 11, 2012
- Sanofi Files Lawsuit against 3 Companies for Approved Allegra Generics
October 11, 2012
- Policy Directions Headed for “Price Cuts for Long-Listed Drugs,” “Price Control for High Priced Drugs”: Prof. Nakamura of Keio Univ.
October 11, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…